March 2023 Content Release Copied
Clinical Profile Documentation
Precision Medicine
Biomarker and lab mappings to support precision medicine diseases including:
- Breast Cancer
- Bile Duct Cancer
- Bladder Cancer
- Endometrial Cancer
- Esophageal Cancer
- Fallopian tube Cancer
- Gastric Cancer
- Head & Neck Cancer
- Hypopharyngeal Cancer
AJCC 8th Edition Staging
- Laryngeal Cancer
- Melanoma, Skin
- Nasopharyngeal Cancer
- Oropharyngeal Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Primary Peritoneal Cancer
- Salivary Gland Cancer
This release contains updates to align with the Cotswold modification of the Ann Arbor system to the Lugano Classification system for the following problem groups:
- Lymphoma, Non-Hodgkins (NHL), Extranodal Marginal Zone B-cell Lymphoma of MALT Type, Gastric
- Lymphoma, Non-Hodgkins (NHL), Extranodal Marginal Zone B-cell Lymphoma of MALT Type, Nongastric
- Lymphoma, Non-Hodgkins (NHL), Follicular
- Lymphoma, Non-Hodgkins (NHL), Nodal Marginal Zone Lymphoma
- Lymphoma, Non-Hodgkins (NHL), Peripheral T Cell Lymphoma
- Lymphoma, Non-Hodgkins (NHL), Primary Cutaneous Lymphoma, Other
- Lymphoma, Non-Hodgkins (NHL), Splenic Marginal Zone Lymphoma
The staging row will display updated Stage values based on the changes. The new content does not affect previous charting documented on existing patients. All previous charting is brought forward during a subsequent visit, just as it did prior to this release.
The following documentation points are now available:
- I
- IE
- II
- IIE
- II bulky*
- III
- IV
- Unknown
Problem Groups
Additions
The Problems > Add Details area is updated with applicable documentation points for the following diagnoses.
ESR1 is available for Breast Cancer with the following documentation points:
- Detected
- Not detected
- Unknown
PD-L1 (CPS) is available for Breast Cancer with the following documentation points:
- CPS =>10
- CPS <10
- Unknown
PD-L1 (CPS) is available for Esophageal Cancer with the following documentation points:
- CPS =>10
- CPS 5-9
- CPS 1-4
- CPS 0
- Unknown
PD-L1 (CPS) is available for Gastric Cancer with the following documentation points:
- CPS =>5
- CPS 1-4
- CPS 0
- Unknown
Residual Tumor is available for Bile Duct and Gallbladder Cancer with the following documentation points:
- R0
- R1
- R2
- RX
- Unknown
Updates
ALK (FISH) display name has been updated to ALK for the following problem group:
- Lung Cancer, Non-small Cell (NSCLC)
FGFR2 for Bladder and Bile Duct Cancers has been updated to include the following documentation point:
- Gene rearrangement (Bile duct only)
Uterine Cancer, Carcinoma has been assigned a pathway (PW) designation to ensure documentation remains synonymous with clinical decision support and ICD-10 mapping.
The following problems now have PW to the left of the problem in the search results:
- Adenocarcinoma of endometrium (disorder)
- Adenocarcinoma of uterus (disorder)
- Carcinoma in situ of body of uterus (disorder)
- Carcinoma in situ of endometrium (disorder)
- Carcinoma in situ of isthmus of uterus (disorder)
- Carcinoma in situ of myometrium (disorder)
- Carcinoma in situ of uterus (disorder)
- Carcinosarcoma of corpus uteri (disorder)
- Carcinosarcoma of uterus (disorder)
- Endometrial carcinoma (disorder)
- Endometrioid carcinoma of endometrium (disorder)
- Malignant epithelial neoplasm of body of uterus (disorder)
- Malignant epithelial neoplasm of fundus of uterus (disorder)
- Malignant epithelial neoplasm of uterus (disorder)
- Primary adenosquamous carcinoma of endometrium (disorder)
- Primary endometrioid carcinoma of endometrium (disorder)
- Primary malignant clear cell neoplasm of endometrium (disorder)
- Primary malignant mixed mullerian neoplasm of endometrium (disorder)
- Primary mixed adenocarcinoma of endometrium (disorder)
- Primary mucinous adenocarcinoma of endometrium (disorder)
- Primary papillary carcinoma of body of uterus (disorder)
- Primary papillary carcinoma of cervix uteri (disorder)
- Primary poorly differentiated endocrine carcinoma of body of uterus (disorder)
- Primary poorly differentiated endocrine carcinoma of cervix uteri (disorder)
- Primary small cell carcinoma of endometrium (disorder)
- Primary squamous cell carcinoma of endometrium (disorder)
- Primary undifferentiated carcinoma of endometrium (disorder)
- Squamous cell carcinoma of cervix (disorder)
- Squamous cell carcinoma of corpus uteri (disorder)
- Transitional cell carcinoma of corpus uteri (disorder)
- Undifferentiated carcinoma of corpus uteri (disorder)
- Undifferentiated carcinoma of endometrium (disorder)
Problems
Additions
New items are available for documentation in Problems and appear in the Charge Capture Report (CCR). Additional ICD-10 codes may be displayed to present surrounding nodes.
| Problem | ICD-10 Codes |
| Personal history of in-situ neoplasm of other and unspecified genital organs | Z86.002 Personal history of in-situ neoplasm of other and unspecified genital organs |
| POT1 gene mutation | Z15.09 Genetic susceptibility to other malignant neoplasm |
Lab Analytes & Panels
Additions
- 18q LOH
- Amylase source
- C11orf30
- C17orf39
- CBC w/auto diff w/OUT reflex
- CBC w/auto diff with reflex
- CD19 total B, %
- CD19 total B, /uL
- CD3 total T, %
- CD3 total T, /uL
- CD3/CD4 helper, %
- CD3/CD4 helper, /uL
- CD3/CD8 suppressor, %
- CD3/CD8 suppressor, /uL
- CD30
- CD3-CD16/56+NK, %
- CD3-CD16/56+NK, /uL
- c-KIT
- CLL mutation analysis amendment result
- Creatinine, Stat nova meter
- EER myeloid malignancies panel by NGS
- Fibrinogen antigen/functional ratio
- Fungal antibody panel interpretation
- HCV quant, NAAT interpretation
- KMT2D (MLL2)
- Molecular tumor testing
- Morphine, urine (cutoff 50 ng/mL)
- MRE11A
- Myeloid malignancies panel interpretation
- Myeloid malignancies panel specimen
- Myeloid malignancy proposed diagnosis
- Myeloid neoplasm mutation analysis amendment result
- NGS for acute myeloid leukemia panel
- NKX2-1 (TTF-1)
- OncoExTra + IHC panel
- OncoExTra panel
- PARK2
- ProPath specimen
- Result comment
- Shiga toxin 1, PCR
- Shiga toxin 2, PCR
- T subset and B-cell quantitative panel
- WHSC1
Medications
Additions
- ABBV-101 invest Oral
- ASP1002 invest IV
Updates
- Mepitel Film
- TST003 invest IV
| Medication | Update |
| BP1001-A invest IV | Form: 2.5 mg/mL (2.5 mg/mL) lyophilized powder for recon soln (also for Research) |
| KSQ-4270 invest Oral | Renamed: KSQ-4279 invest Oral |
| Lidocaine Infiltrate 10 mg/mL (1%) | New default SIG: Lidocaine 10 mg subcutaneously once |
| Lidocaine Infiltrate 20 mg/mL (2%) | New default SIG: Lidocaine 20 mg subcutaneously once |
| Pegfilgrastim Subcutaneous | Removed default route: via continuous sub-Q infusion (use wearable injector) |
| Ublituximab-xiiy IV (Briumvi) | Max Single Dose: 450 mg
New default SIG: 150 mg intravenously Piggyback once; admixture fluid 250 mL Instructions: Dilute in 250 mL of NS. Gently invert to mix – do NOT shake. First dose: 150 mg. Administer at an initial rate of 10 mL/hr for the first 30 minutes, increase to 20 mL/hr for the next 30 minutes, increase to 35 mL/hr for the next 60 minutes, and increase to 100 mL/hr for the remaining 2 hrs. Subsequent doses: 450 mg. Administer at an initial rate of 100 mL/hr for the first 30 minutes, then increase to 400 mL/hr for the remaining 30 minutes. Observe patient for at least one hour after completion of first two infusions. |
Regimen Library
Additions
| Regimen Name | Diagnosis |
| Capecitabine + XRT Q42D (Anal) | Anal Cancer (Parent) |
| Darbepoetin alfa Q14D (MDS) Supportive Care | Myelodysplastic Syndrome (MDS) |
| Elacestrant + Goserelin Q28D | Breast Cancer |
| Elacestrant + Leuprolide Q28D | Breast Cancer |
| Epoetin alfa Q7D (MDS) Supportive Care | Myelodysplastic Syndrome (MDS) |
| Lomustine + Bevacizumab (10 mg/kg) D1,15,29 Q42D | Brain Tumor (Parent) |
| Trabectedin + Doxorubicin Q21D fb Trabectedin Q21D | Uterine Cancer (Parent); Soft Tissue Sarcoma (Parent) |
| Ublituximab-xiiy D1,15 fb D1 Q6M | Multiple Sclerosis |
Updates
Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.
- All Malignancies
- Anal Cancer (Parent)
- Arthritis, Rheumatoid
- Bile Duct Cancer (Parent)
- Breast Cancer
- Colon Cancer
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gallbladder Cancer
- Gastric Cancer
- Leukemia, Acute Myeloid (AML)
- Leukemia, Chronic Lymphocytic (CLL)
- Leukemia, Chronic Myelomonocytic (CMML)
- Lung Cancer, Non-small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Melanoma, Skin
- Multiple Myeloma (MM)
- Myelodysplastic Syndrome (MDS)
- Myelofibrosis
- Myeloproliferative Disorder
- Ovarian and Primary Peritoneal Cancer
- Neuroendocrine Tumor, Carcinoid (Parent)
- Pancreatic Cancer, Carcinoid/Neuroendocrine
- Prostate Cancer
- Rectal Cancer
- Renal Cell Carcinoma (RCC)
- Waldenstrom’s Macroglobulinemia
Renames
| Previous Name | New Name |
| Carfilzomib D1,2,8,9,15,16 + Cyclophosphamide PO D1,8,15 + Dexamethasone D1,8,15,22 Q28D (Induction) | Carfilzomib D1,2,8,9,15,16 + Cyclophosphamide PO D1,8,15 + Dexamethasone Q28D (Induction) |
| Carfilzomib D1,2,8,9,15,16 + Dexamethasone D1,2,8,9,15,16,22,23 Q28D | Carfilzomib D1,2,8,9,15,16 + Dexamethasone Q28D |
| Carfilzomib D1,2,8,9,15,16 fb D1,2,15,16 + Pomalidomide D1-21 + Dexamethasone D1,8,15,22 Q28D | Carfilzomib D1,2,8,9,15,16 fb D1,2,15,16 + Pomalidomide D1-21 + Dexamethasone Q28D |
| Carfilzomib D1,8,15 + Dexamethasone D1,8,15,22 fb D1,8,15 Q28D | Carfilzomib D1,8,15 + Dexamethasone Q28D |
Research
Updates
| Updated Reference Information | Updated Drug Service Order Information | Updated Regimen Instructions< | Other Changes | |
| USOR 20175 | X | X | ||
| USOR 20176 | X | X | ||
| USOR 20298 | X | X | No longer available: USOR 20298 VS-6766 Monotherapy | |
| USOR 20408 | X | X | X | |
| USOR 21207 | X | X | X | |
| USOR 21235 | X | |||
| USOR 21282 | X | X | ||
| USOR 21527 | X | |||
| USOR 22005 | X | X | X | |
| USOR 22033 | X | X | ||
| USOR 22052 | X | X | X | |
| USOR 22123 | X | |||
| USOR 22141 | X | |||
| USOR 22169 | X | X | X | |
| USOR 22201 | X | X | X | |
| USOR 22242 | X | X |
Billing & HCPCS Codes
Updates
Please visit CMS’s website for a complete list of April 2023 HCPCS Quarterly updates.
| Medication | HCPCS |
| Antihemophilic Factor VIII (Recomb, Fc-VWF-XTEN,BDD-eht) | J3490 per 50 units |
| Calcium Gluconate IV | J0612 & J0613 per
|
| Calcium Gluconate Intraosseous | J0612 & J0613 per
|
| Ebola (Zaire) Vaccine, Live, Vero (PF) | 90758 per 1 mL |
| Eflapegrastim-xnst | J1449 per 0.1mg |
| Etranacogene Dezaparvovec-drlb | J1411 per 2x10e13 gc |
| Gemcitabine Intravesical | J9196 per 200 mg |
| Gemcitabine IV | J9196 per 200 mg |
| Hydrocortisone (PF) Intrathecal | J1720 per 100 mg |
| Influenza Virus Vaccine (PF) IM Quad-Split (6 months & older) (Fluarix/Flulaval) | 90686 per 0.5 mL |
| Insulin Glargine-aglr Subcutaneous Pen 100 unit/mL | J3490 per 100 units |
| Lidocaine Intradermal 2% | J2001
|
| Naloxone Nasal Spray 4 mg/actuation | J3490 per
|
| Olipudase alfa-rpcp | J0218 per 1 mg |
| Pegcetacoplan (PF) Intravitreal | J3490 per 150 mg |
| Pegfilgrastim-fpgk | Q5127 per 0.5 mg |
| Pegfilgrastim-pbbk | Q5130 per 0.5 mg |
| Pemetrexed | J9294 per 10 mg J9296 per 10 mg J9297 per 10 mg J9314 per 10 mg |
| Ranibizumab-eqrn Intravitreal | Q0138 per 0.1 mg |
| Sodium Thiosulfate IV (Pedmark) | J0208 per
|
| Spesolimab-sbzo | J1747 per 1 mg |
HCPCS & NDC Crosswalk
Additions
Updates effective April 1, 2023.
| Medication & Brand | HCPCS Code | NDC |
| Calcium gluconate (fresenius kabi) | J0612 per 10 mg | 63323036001 65219016210 63323036003 63323036019 63323036059 63323036005 65219016201 65219016401 65219016450 63323036061 |
| Calcium gluconate (wg critical care) | J0613 per 10 mg | 44567062001 44567062024 44567062101 44567062124 44567062201 44567062224 |
| Gemcitabine (accord) | J9196 per 200 mg | 16729039130 16729041903 16729042333 16729042605 |
| Pemetrexed (hospira) | J9294 per 10 mg | 00409218801 00409002002 00409002103 00409104501 00409353201 00409000404 |
| Pemetrexed (accord) | J9296 per 10 mg | 16729022903 16729023011 16729024438 16729052205 16729052235 16729052264 16729052228 |
| Pemetrexed (sandoz) | J9297 per 10 mg | 00781351990 00781352091 00781351876 |
| Pemetrexed (teva) | J9314 per 10 mg | 00480451401 00480451501 00480451601 |